3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Cognitive Dysfunction
1
Alzheimer Disease
1
Interventions
Rituximab
25
Lenalidomide
21
Cyclophosphamide
20
Prednisone
14
obinutuzumab
12
Vincristine
12
Doxorubicin
11
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
9
Specimen Handling
8
ibrutinib
7
Biopsy
7
fludarabine
6
pembrolizumab
5
fludarabine phosphate
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
zanubrutinib
4
venetoclax
4
tazemetostat
4
Whole-Body Irradiation
4
R-CHOP protocol
4
Prednisolone
3
Mycophenolic Acid
3
Etoposide
3
Cyclosporine
3
tisagenlecleucel
2
polatuzumab vedotin
2
orelabrutinib
2
loncastuximab tesirine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
fasudil
×
90 days
×
Clear all
NCT06362707
2026-05-04
FEAD
Helse Stavanger HF
Phase 2
Recruiting
200 enrolled